Stockreport

U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

NovoCure Limited - Ordinary Shares  (NVCR) 
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
PDF Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancerPhase 3 PAN [Read more]